1-甲基-1H-1,2,4-三唑-3-胺 | 49607-51-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-1H-1,2,4-三唑-3-胺
• 中文别名: 1-甲基-1H-[1,2,4]噻唑-3-胺双盐酸盐
• 英文名称: 1-methyl-1H-1,2,4-triazol-3-amine
• 英文别名: 3-amino-1-methyl-1,2,4-triazole；3-amino-1-methyl-1H-1,2,4-triazole；3-Amino-1-methyl-1,2,4-triazol；1-methyl-1,2,4-triazol-3-amine
• CAS: 49607-51-4
• 化学式: C₃H₆N₄
• mdl: MFCD02853162
• 分子量: 98.1074
• InChiKey: CNSCXLZIKKHZND-UHFFFAOYSA-N

物化性质

• 熔点：
  81-86℃
• 沸点：
  281.9±23.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（少量）、甲醇（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-1,2,4-三唑-3-胺 以9%的产率得到
  参考文献：
  名称：

  STEPANOV, S. D.;PEVZNER, M. S.;TEMCHENKO, T. P., ZH. ORGAN. XIMII, 24,(1988) N 10, S. 2145-2151

  摘要：

  DOI：
• 作为产物：
  描述：

  1-methyl-1,2,4-triazol-3-amine;hydroiodide 以36%的产率得到
  参考文献：
  名称：

  HANS M., WISS. Z. PAED. HOCHSCH. LISELOTTE HERRMANN GUESTROW. MATH.-NATURWISS. FAK+

  摘要：

  DOI：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• 4-Chlorocolchicine derivatives bearing a thiourea side chain at the C-7 position as potent anticancer agents
  作者：Hiroyuki Nishiyama、Masahiro Ono、Takuya Sugimoto、Toshio Sasai、Naoyuki Asakawa、Satoshi Ueno、Yoshitaka Tominaga、Takashi Yaegashi、Masato Nagaoka、Takeshi Matsuzaki、Noriyuki Kogure、Mariko Kitajima、Hiromitsu Takayama

  DOI：10.1039/c3md00287j

  日期：——

  A series of 4-substituted colchicine derivatives were synthesized and evaluated with an eye toward developing new anticancer agents. As a result, 4-chlorocolchicine derivatives bearing a thioureide side chain at the C-7 position were found to exhibit significant cytotoxicities to three human cancer cell lines (A549, HT-29, and HCT116). In particular, compound 26 having an ethylthioureide group at the C-7 had high antitumor activity in vivo and a broad effective dosage range. Furthermore, compound 58, which has a (5-methylpyrazol-3-yl)thioureide group at the C-7 side chain, exhibited strong cytotoxicity and desirable metabolic stability in vitro.

  合成了一系列4-取代的秋水仙碱衍生物，并对其进行了评估，旨在开发新型抗癌药物。结果发现，在C-7位带有硫脲侧链的4-氯秋水仙碱衍生物对三种人癌细胞系（A549、HT-29和HCT116）显示出显著的细胞毒性。特别是，在C-7位带有乙基硫脲的化合物26在体内具有高抗肿瘤活性，并且有效剂量范围广泛。此外，在C-7位侧链带有(5-甲基吡唑-3-基)硫脲的化合物58，在体外表现出强烈的细胞毒性和良好的代谢稳定性。
• Thiazole-4-carboxyamide derivatives
  申请人：Buettelmann Bernd

  公开号：US20060160857A1

  公开（公告）日：2006-07-20

  The present invention is concerned with novel thiazole 4-carboxyamide derivatives of the general formula (I) and with methods for the preparation thereof, which compounds are useful as metabotropic glutamate receptor antagonists: wherein R 1 to R 4 are as defined in the specification.

  本发明涉及一种新型噻唑-4-羧酰胺衍生物，其通式为（I），以及其制备方法，这些化合物可用作代谢型谷氨酸受体拮抗剂： 其中R1至R4如规范中所定义。
• HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160237059A1

  公开（公告）日：2016-08-18

  The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.

  本申请涉及新颖的杂环取代的6-(三氟甲基)嘧啶-4(3H)-酮衍生物，其制备方法，它们单独或组合用于治疗和/或预防疾病，以及它们用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管、肾脏、炎症和纤维化疾病。